Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evalueringen af ​​PC14586 hos patienter med avancerede solide tumorer, der huser en p53 Y220C-mutation

1. oktober 2026 opdateret af: PMV Pharmaceuticals, Inc

Et fase 1/2 åbent, multicenter-studie til vurdering af sikkerhed, tolerabilitet, farmakokinetik, farmakodynamik og effektivitet af PC14586 hos patienter med avancerede solide tumorer, der huser en p53 Y220C-mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

Rezatapopt is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

The primary objective of Phase 2 Monotherapy is to evaluate the efficacy of rezatapopt at the Recommended Phase 2 Dose (RP2D) including the Overall Response Rate (ORR) in the Ovarian Cancer Cohort and the ORR across all cohorts as determined by blinded independent central review. Secondary objectives of Phase 2 are to characterize the safety, pharmacokinetic (PK) properties, quality of life, and other efficacy measures of PC14586 rezatapopt at the RP2D. Enrollment is open for the Phase 2 Monotherapy portion of the study.

The primary objective of Phase 1 Monotherapy is to establish the maximum tolerated dose (MTD) and RP2D of rezatapopt. Secondary objectives are to characterize the PK properties, safety and tolerability, and to assess preliminary efficacy including ORR. Enrollment into Phase 1 Monotherapy is complete.

The primary objective of Phase 1b Combination Therapy is to establish the MTD/RP2D of rezatapopt when administered in combination with pembrolizumab. Secondary objectives of Phase 1b Combination Therapy are to characterize PK, safety and tolerability, and to assess preliminary efficacy of rezatapopt when administered in combination with pembrolizumab, including ORR. Enrollment into Phase 1b Combination Therapy is complete.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

300

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australien
        • Rekruttering
        • Chris O'Brien Lifehouse Hospital
        • Kontakt:
          • Peter Grimison, MD
    • Queensland
      • South Brisbane, Queensland, Australien
        • Rekruttering
        • Mater Cancer Care Centre
        • Kontakt:
          • Catherine Shannon, MD
    • South Australia
      • Bedford Park, South Australia, Australien
        • Rekruttering
        • Flinders Medical Center
        • Kontakt:
          • Shawgi Sukumaran, MD
    • Victoria
      • Clayton, Victoria, Australien
        • Rekruttering
        • Monash Medical Centre
        • Kontakt:
          • Sophia Frentzas, MD
    • Western Australia
      • Nedlands, Western Australia, Australien
        • Rekruttering
        • Linear Clinical Research
        • Kontakt:
          • Michael Millward, MD
    • Middlesex
      • London, Middlesex, Det Forenede Kongerige
        • Rekruttering
        • Sarah Cannon Research Institute UK
        • Kontakt:
          • Elisa Fontana, MD, PhD
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, Det Forenede Kongerige
        • Rekruttering
        • Freeman Hospital
        • Kontakt:
          • Alastair Greystoke, MB ChB PhD
    • California
      • Irvine, California, Forenede Stater, 92868
        • Trukket tilbage
        • University of California Irvine Chao Family Comprehensive Cancer Center
      • La Jolla, California, Forenede Stater, 92093
        • Rekruttering
        • University of San Diego Moores Cancer Center
        • Kontakt:
          • Shumei Kato, MD
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • USC Norris Comprehensive Cancer Center
        • Kontakt:
          • Anthony El-Khoueiry, MD
      • Los Angeles, California, Forenede Stater, 90024
        • Rekruttering
        • UCLA Jonsson Comprehensive Cancer Center
        • Kontakt:
          • Gottfried Konecny, MD
    • Colorado
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Rocky Mountain Cancer Center
        • Kontakt:
          • Allen Cohn, MD
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Rekruttering
        • Yale Cancer Center
        • Kontakt:
          • Patricia LoRusso, MD
    • Delaware
      • Newark, Delaware, Forenede Stater, 19713
        • Rekruttering
        • Medical Oncology Hematology Consultants
        • Kontakt:
          • Jamal Misleh, MD
    • Florida
      • Miami, Florida, Forenede Stater, 33136
        • Rekruttering
        • University of Miami - Sylvester Comprehensive Cancer Center
        • Kontakt:
          • Gilberto de Lima Lopes Jr., MD
      • Orlando, Florida, Forenede Stater, 32803
        • Rekruttering
        • Advent Health
        • Kontakt:
          • Robert Holloway, MD
      • Port Charlotte, Florida, Forenede Stater, 33980
        • Rekruttering
        • Florida Cancer Specialists South
        • Kontakt:
          • Ivor Percent, MD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Kontakt:
          • Aparna Parikh, MD
      • Boston, Massachusetts, Forenede Stater, 02215
        • Rekruttering
        • Dana Farber Cancer Institute
        • Kontakt:
          • Geoffrey Shapiro, MD, PhD
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Afsluttet
        • Karmanos Cancer Institute
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering
        • Kontakt:
          • Alison Schram, MD
      • New York, New York, Forenede Stater, 10032
        • Ikke rekrutterer endnu
        • Columbia University Medical Center
        • Kontakt:
          • June Hou, MD
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke University
        • Kontakt:
          • Niharika Mettu, MD, PhD
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • The Cleveland Clinic Taussig Cancer Center
        • Kontakt:
          • Dale Shepard, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma
        • Kontakt:
          • Debra Richardson, MD
    • Oregon
      • Portland, Oregon, Forenede Stater, 97210
        • Rekruttering
        • Oregon Health & Science University (OHSU)
        • Kontakt:
          • Shivaani Kummar, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Abramson Cancer Center of the University of Pennsylvania
        • Kontakt:
          • Lainie Martin, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Kontakt:
          • Sarah Taylor, MD, PhD
      • York, Pennsylvania, Forenede Stater, 17403
        • Rekruttering
        • WellSpan York Cancer Center
        • Kontakt:
          • Ikechukwu Akunyili, MD
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Afsluttet
        • Medical University of South Carolina
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute
        • Kontakt:
          • Melissa Johnson, MD
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Rekruttering
        • New Experimental Therapeutics - NEXT Oncology
        • Kontakt:
          • David Sommerhalder, MD
      • Bedford, Texas, Forenede Stater, 76022
        • Rekruttering
        • Texas Oncology
        • Kontakt:
          • Terrence Wong, MD
      • Dallas, Texas, Forenede Stater, 75390
        • Rekruttering
        • UT Southwest Simmons Cancer Center
        • Kontakt:
          • David Miller, MD
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • The University of Texas MD Anderson Cancer Center
        • Kontakt:
          • Ecaterina Dumbrava, MD
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • New Experimental Therapeutics of San Antonio - NEXT Oncology
        • Kontakt:
          • David Sommerhalder, MD
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • Virginia Cancer Specialists
        • Kontakt:
          • Alexander Spira, MD
    • Washington
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • University of Washington, Fred Hutchinson Cancer Center
        • Kontakt:
          • Andrew Coveler, MD
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53705
        • Rekruttering
        • University of Wisconsin Carbone Cancer Center
        • Kontakt:
          • Nataliya Uboha, MD, PhD
      • Lyon, Frankrig
        • Rekruttering
        • Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer
        • Kontakt:
          • Isabelle Ray-Coquard, MD
      • Nîmes, Frankrig, 30900
        • Rekruttering
        • CHU de Nîmes
        • Kontakt:
          • Frédéric Fiteni, MD, PhD
      • Vandœuvre-lès-Nancy, Frankrig, 54519
        • Rekruttering
        • Institute Cancer De Lorraine
        • Kontakt:
          • Aurélien Lambert, MD
    • Bas-Rhin
      • Strasbourg, Bas-Rhin, Frankrig
        • Rekruttering
        • ICANS - Institut de cancérologie Strasbourg Europe
        • Kontakt:
          • Lauriane Eberst, MD
    • Gironde
      • Bordeaux, Gironde, Frankrig
        • Rekruttering
        • Institut Bergonie
        • Kontakt:
          • Veronique Debien, MD
    • Haute-Garonne
      • Toulouse, Haute-Garonne, Frankrig
        • Rekruttering
        • Institut Claudius Regaud
        • Kontakt:
          • Carlos-Alberto Gomez-Roca, MD
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, Frankrig
        • Rekruttering
        • EDOG Institut de Cancerologie de l'Ouest
        • Kontakt:
          • Jean-Sebastien Frenel, MD
    • Puy-de-Dôme
      • Clermont-Ferrand, Puy-de-Dôme, Frankrig
        • Rekruttering
        • Centre Jean Perrin
        • Kontakt:
          • Xavier Durando, MD
    • Val-de-Marne
      • Villejuif, Val-de-Marne, Frankrig
        • Rekruttering
        • Institut Gustave Roussy
        • Kontakt:
          • Yohann Loriot, MD
      • Milan, Italien
        • Rekruttering
        • Humanitas San Pio X
        • Kontakt:
          • Domenica Lorusso, MD
      • Naples, Italien, 80131
        • Rekruttering
        • IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale
        • Kontakt:
          • Anna Passarelli, MD
    • Lazio
      • Rome, Lazio, Italien
        • Rekruttering
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Kontakt:
          • Anna Fagotti, MD
      • Rome, Lazio, Italien
        • Rekruttering
        • Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
        • Kontakt:
          • Lorenza Landi, MD
    • Lombardy
      • Milan, Lombardy, Italien
        • Rekruttering
        • ASST Grande Ospedale Metropolitano Niguarda
        • Kontakt:
          • Salvatore Siena, MD
      • Milan, Lombardy, Italien
        • Rekruttering
        • Fondazione IRCCS Istituto Nazionale Dei Tumori
        • Kontakt:
          • Massimo Di Nicola, MD
      • Milan, Lombardy, Italien
        • Rekruttering
        • Istituto Europeo Di Oncologia
        • Kontakt:
          • Giuseppe Curigliano, MD
      • Rozzano, Lombardy, Italien
        • Rekruttering
        • Istituto Clinico Humanitas
        • Kontakt:
          • Armando Santoro, MD
    • Torino
      • Candiolo, Torino, Italien
        • Rekruttering
        • Fondazione del Piemonte per l'Oncologia (IRCCS)
        • Kontakt:
          • Chiara Lazzari, MD
      • Kent Ridge, Singapore
        • Rekruttering
        • National University Hospital
        • Kontakt:
          • David Shao Peng Tan, MD
      • Singapore, Singapore, 168582
        • Rekruttering
        • National Cancer Center of Singapore
        • Kontakt:
          • Tira Tan, MD
      • Barcelona, Spanien
        • Rekruttering
        • NEXT Oncology-Hospital Quironsalud Barcelona
        • Kontakt:
          • Elena Garralda, MD
      • Barcelona, Spanien
        • Rekruttering
        • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
        • Kontakt:
          • Lorena Farinas, MD
      • Madrid, Spanien, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
        • Kontakt:
          • Santiago Ponce Aix, MD
      • Rioja, Spanien
        • Rekruttering
        • START Rioja
        • Kontakt:
          • Jorge Luis Ramon Patino, MD
      • Valencia, Spanien
        • Rekruttering
        • Hospital Clinico Universitario de Valencia
        • Kontakt:
          • José Alejandro Pérez Fidalgo, MD
    • Madrid
      • Madrid, Madrid, Spanien
        • Rekruttering
        • START MADRID_Hospital Universitario Fundacion Jimenez Diaz
        • Kontakt:
          • Victor Moreno Garcia, MD
      • Madrid, Madrid, Spanien
        • Rekruttering
        • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
        • Kontakt:
          • Irene Moreno, MD
      • Seoul, Sydkorea
        • Rekruttering
        • Samsung Medical Center
        • Kontakt:
          • Chel Hun Choi, MD
      • Seoul, Sydkorea
        • Rekruttering
        • Asan Medical Center
        • Kontakt:
          • Dae Ho Lee, MD
      • Seoul, Sydkorea
        • Rekruttering
        • Seoul University Hospital
        • Kontakt:
          • Seock-Ah Im, MD
      • Seoul, Sydkorea
        • Rekruttering
        • Severance Hospital Yonsei University
        • Kontakt:
          • Jung-Yun Lee, MD
      • Seoul, Sydkorea
        • Rekruttering
        • National Cancer Center
        • Kontakt:
          • Myong Cheol Lim, MD, PhD
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Tyskland
        • Rekruttering
        • Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg
        • Kontakt:
          • Martin Haag, MD
    • Bavaria
      • Augsburg, Bavaria, Tyskland
        • Rekruttering
        • Universitätsklinikum Augsburg
        • Kontakt:
          • Rainer Claus, MD
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Tyskland
        • Rekruttering
        • Asklepios Klinik Altona
        • Kontakt:
          • Dirk Arnold, MD
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland
        • Trukket tilbage
        • Universitätsklinikum Frankfurt
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland
        • Rekruttering
        • Universitätsklinikum Essen
        • Kontakt:
          • Marcel Wiesweg, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.
  • Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation
  • Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
  • Previously treated with one or more lines of anticancer therapy and progressive disease
  • Adequate organ function
  • Measurable disease per RECIST v1.1 (Phase 2)

Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)

  • Anti-PD-1/PD-L1 naive or must have progressed on treatment
  • Measurable disease

Exclusion Criteria:

  • Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug
  • Radiotherapy within 14 days of receiving the study drug
  • Primary CNS tumor
  • History of leptomeningeal disease or spinal cord compression
  • Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms
  • Stroke or transient ischemic attack within 6 months prior to screening
  • Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities
  • Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt
  • History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication
  • History of prior organ transplant
  • Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
  • Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection

Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)

  • Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2). Exception: Ovarian cancer patients with a known KRAS SNV are permitted.

Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)

  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)
  • Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention
  • Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug
  • Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • History of radiation pneumonitis
  • History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids
  • Active infection requiring systemic therapy
  • Known history of HIV infection
  • Has previously received rezatapopt

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1 Monotherapy Dose Escalation

Multiple dose levels of daily oral rezatapopt will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of rezatapopt to recommend a Phase 2 dose (RP2D).

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586
Eksperimentel: Phase 1b Combination Therapy Dose Escalation, Part 1

Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Andre navne:
  • MK-3475
  • KEYTRUDA®
  • KEYNOTE-D79
  • MK-3475-D79
Eksperimentel: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients

Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Andre navne:
  • MK-3475
  • KEYTRUDA®
  • KEYNOTE-D79
  • MK-3475-D79
Eksperimentel: Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients

Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586

Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Andre navne:
  • MK-3475
  • KEYTRUDA®
  • KEYNOTE-D79
  • MK-3475-D79
Eksperimentel: Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586
Eksperimentel: Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586
Eksperimentel: Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586
Eksperimentel: Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586
Eksperimentel: Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort

Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.

First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.

Andre navne:
  • PC14586

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt
Tidsramme: 40 months

Number of participants with treatment related adverse events

40 months
Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D)
Tidsramme: 30 months

RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data

30 months
Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1)
Tidsramme: The first 28 days of treatment (Cycle 1) per patient

Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt

The first 28 days of treatment (Cycle 1) per patient
Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
Tidsramme: 18 months for treatment arm

Number of participants with treatment related adverse events

18 months for treatment arm
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of rezatapopt when administered in combination with pembrolizumab
Tidsramme: The first 28 days of combination treatment arm (starting on Day -7) per patient

Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt

The first 28 days of combination treatment arm (starting on Day -7) per patient
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of rezatapopt when administered in combination with pembrolizumab
Tidsramme: 18 months

RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data

18 months
Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
Tidsramme: 12 months for treatment arm

Number of participants with treatment related adverse events

12 months for treatment arm
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt
Tidsramme: 34 months

Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review across all cohorts

34 months
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt in ovarian cancer patients
Tidsramme: 34 months

Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review in the ovarian cancer cohort

34 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 and metabolites when rezatapopt is administered orally.
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Blood plasma concentration

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 1 Monotherapy (Dose Escalation): Overall Response Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Time to Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Duration of Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Disease Control Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Progression Free Survival per RECIST v1.1 or PCWG3 modified RECIST v1.1
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1 Monotherapy (Dose Escalation): Overall Survival
Tidsramme: 41 months for study (end of Phase 1)

Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent

41 months for study (end of Phase 1)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Peak concentration (Cmax)
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Time of peak concentration (Tmax)
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Trough observed concentrations (Ctrough/Ctau)
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally in combination with pembrolizumab.
Tidsramme: Approximately 12 months per patient (30 months for treatment arm)

Blood plasma concentration

Approximately 12 months per patient (30 months for treatment arm)
Phase 1b Combination Therapy: Overall Response Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Time to Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Duration of Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Disease Control Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Overall Survival
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Determine the number and type of adverse events to characterize the safety of rezatapopt
Tidsramme: 30 months for study (end of Phase 1b)

Number of participants with treatment related adverse events

30 months for study (end of Phase 1b)
Phase 1b Combination Therapy: Progression Free Survival per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
Tidsramme: 30 months for study (end of Phase 1b)

Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab

30 months for study (end of Phase 1b)
Phase 2 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally.
Tidsramme: Approximately 12 months per patient (75 months for Phase 1 and Phase 2)

Blood plasma concentration

Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
Phase 2 Monotherapy (Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt
Tidsramme: 34 months for study (end of Phase 2)

Number of participants with treatment related adverse events

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate across all cohorts per RECIST v1.1 as assessed by Investigator
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Time to Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Time to Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Duration of Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Duration of Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Survival in ovarian cancer cohort
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Overall Survival across all cohorts
Tidsramme: 34 months for study (end of Phase 2)

Evaluation of anti-tumor activity of rezatapopt as a single agent

34 months for study (end of Phase 2)
Phase 2 Monotherapy (Dose Expansion): Quality of life assessment
Tidsramme: Evaluated at every visit. 34 months for treatment arm (end of Phase 2)

Changes from baseline in quality of life as measured by a validated instrument, for participants 18 and older

Evaluated at every visit. 34 months for treatment arm (end of Phase 2)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Marc Fellous, MD, Sr. Vice President, Clinical Development and Medical Affairs

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. oktober 2020

Primær færdiggørelse (Anslået)

15. december 2026

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

1. oktober 2020

Først indsendt, der opfyldte QC-kriterier

7. oktober 2020

Først opslået (Faktiske)

14. oktober 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PMV-586-101
  • KEYNOTE-D79 (Registry Identifier: Merck, Sharp & Dohme, LLC)
  • MK-3475-D79 (Registry Identifier: Merck, Sharp & Dohme, LLC)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .